CA
STOK icon

Clearstead Advisors’s Stoke Therapeutics STOK Stock Holding History

Clearstead Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99 Buy
+3
New +$96 ﹤0.01% 3358

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Clearstead Advisors's STOK Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 3 shares worth $99. The stake represents ﹤0.01% of the portfolio and ranks #3358 among its holdings.

58 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Clearstead Advisors held 3 shares of Stoke Therapeutics worth $99 as of Q2 2026.
  • Stoke Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3358 holding.
  • 58 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.